Qi Lu and others besieged 600 million anti-tumor injections!

Medical Network News on March 3 A few days ago, the official website of the State Food and Drug Administration showed that Jiangsu Haosen Pharmaceutical's supplementary application for decitabine for injection was approved
.
Prior to this, no company has reviewed decitabine for injection
.
According to data from Menet.
com, the sales of terminal decitabine injections in China's public medical institutions exceeded 600 million yuan in 2019, with a year-on-year increase of 3.
87% in the first half of 2020
.
There are 8 manufacturers of decitabine for injection, including Jiangsu Haosen Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group, Qilu Pharmaceutical (Hainan), and Xian Yangsen.
Among them, Jiangsu Hausen Pharmaceutical has the largest market share, exceeding 45%, followed by It is more than 35% of CP Tianqing Pharmaceutical Group
.
On February 26, 2021, the drug approval document pending information is released.
In recent years, the sales of terminal decitabine injections in public medical institutions in China.
Source: The terminal competition pattern of public medical institutions in China.
Decitabine is suitable for the treatment of myelodysplastic syndrome MDS)
.
According to data from Meinnet.
com, in recent years , the sales of terminal decitabine injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, exceeding 600 million yuan in 2019.
In the first half of the year, it increased by 3.
87% year-on-year
.
There are 8 manufacturers of decitabine for injection, including Jiangsu Haosen Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group, Qilu Pharmaceutical (Hainan), and Xian Yangsen.
Among them, Jiangsu Hausen Pharmaceutical has the largest market share, exceeding 45%, followed by It is more than 35% of CP Tianqing Pharmaceutical Group
.
Source: MED2.
0 China Drug Evaluation Database.
In terms of consistency evaluation, before this, no company has evaluated decitabine for injection
.
At present, the product has 4 companies including Zhengda Tianqing Pharmaceutical Group, Qilu Pharmaceutical (Hainan), Jiangsu Aosaikang Pharmaceutical, etc.
, to supplement the application under review (in the drug review center)
.
In addition, Jianjin Pharmaceuticals submitted a marketing application in the 4 generic categories under review and approval (at the Center for Drug Appraisal).
After approval, it will be deemed as over-evaluated.

.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database